FI113542B - Steroider som innehåller en 17-spirometylenlaktongrupp - Google Patents

Steroider som innehåller en 17-spirometylenlaktongrupp Download PDF

Info

Publication number
FI113542B
FI113542B FI955108A FI955108A FI113542B FI 113542 B FI113542 B FI 113542B FI 955108 A FI955108 A FI 955108A FI 955108 A FI955108 A FI 955108A FI 113542 B FI113542 B FI 113542B
Authority
FI
Finland
Prior art keywords
hydroxy
lactone
diene
norcola
solution
Prior art date
Application number
FI955108A
Other languages
English (en)
Finnish (fi)
Other versions
FI955108A0 (sv
FI955108A (sv
Inventor
Johannes Antonius Mar Hamersma
Der Louw Jaap Van
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of FI955108A0 publication Critical patent/FI955108A0/sv
Publication of FI955108A publication Critical patent/FI955108A/sv
Application granted granted Critical
Publication of FI113542B publication Critical patent/FI113542B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J19/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 by a lactone ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0092—Alkenyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/001—Lactones
    • C07J21/003—Lactones at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (6)

1. Steroid med en 17-spirometylenlaktongrupp med formeln I 15 kännetecknad av att Ri är Ο, (Η, Η) , (H, OR) eller NOR, där R är vald frän gruppen H, (1-6C) alkyl och (1-6C)acyl; R2 är H, (1-6C)alkyl, som är valbart substituerad 20 med en halogen, (2-6C)alkenyl, som är valbart substituerad med en halogen, (2-6C)alkynyl, som är valbart substituerad • · ίί: med en halogen, eller en halogen; R2' är H; eller R2' tillsammans med R2 är en (1- ·;·· 6C) alkylidengrupp eller (2-6C) alkenylidengrupp; eller R2f : 25 tillsammans med R3 är en bindning; , R3 är H, if all den inte bildar en bindning tillsammans med R2' ; R4 är (1-6C)alkyl; den ena av R5 och R6 är väte och den andra är väte 30 eller (1-6C)alkyl; X är (CH2) n eller (CnH2n-2) / där n är 2 eller 3, valbart substituerad med en grupp hydroxi, halogen, (1-,··1, 6C) alkyl, (l-6C)acyl, (7-9C) fenylalkyl, vilken fenylgrupp ( kan vara substituerad med en grupp (1-6C)alkyl, (1- h’ 35 6C)alkoxi, hydroxi eller halogen; Λ! Y är 0 eller (H, OH); och 113542 48 den brutna linjen är en valbar bindning, varav ätminstone en av bindningarna 4-5, 5-10 och 9-10 är en dubbelbindning.
2. Steroid enligt patentkrav 1, kännetecknad 5 av att Ri är 0; R4 är metyl, Y är 0 och n är 2.
3. Steroid enligt patentkrav 2, kännetecknad av att Ri är 0, R2 är (1-6C)alkyl eller (2-6C)alkynyl, R2' och R3 är H, R4 är metyl, R5 och R6 är väte, X är (CH2)2, Y är 0 och den brutna linjen i D-ringen är inte en bindning 10 och den andra brutna linjen är en 4-5 bindning.
4. Steroid enligt patentkrav 1, kännetecknad av att den är (11β,17α)-ll-etyl-17-hydroxi-3-oxo-19-nor-kola-4,20-dien-24-oinsyra-6-lakton eller (11β,17a)-17- hydroxi-3-oxo-ll-(1-propynyl)-19-norkola-4,20-dien-24-oin- 15 syra-6-lakton.
5. Farmaceutisk komposition, kännetecknad av att den innehäller en steroid enligt nägot av patentkraven 1-4 och farmaceutiskt godtagbara tillsatsämnen.
6. Användning av en steroid enligt nägot av pa- 20 tentkraven 1-4, kännetecknad av att den används för framställning av ett läkemedel med progesteronaktivitet. » » • * · > « ♦ · * > ! · 1 » I I •
FI955108A 1994-10-27 1995-10-26 Steroider som innehåller en 17-spirometylenlaktongrupp FI113542B (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94203117 1994-10-27
EP94203117 1994-10-27

Publications (3)

Publication Number Publication Date
FI955108A0 FI955108A0 (sv) 1995-10-26
FI955108A FI955108A (sv) 1996-04-28
FI113542B true FI113542B (sv) 2004-05-14

Family

ID=8217314

Family Applications (1)

Application Number Title Priority Date Filing Date
FI955108A FI113542B (sv) 1994-10-27 1995-10-26 Steroider som innehåller en 17-spirometylenlaktongrupp

Country Status (26)

Country Link
US (1) US5741786A (sv)
EP (1) EP0709394B1 (sv)
JP (1) JPH08225590A (sv)
KR (1) KR100402636B1 (sv)
CN (1) CN1052237C (sv)
AT (1) ATE199015T1 (sv)
AU (1) AU689642B2 (sv)
BR (1) BR9504576A (sv)
CA (1) CA2161490A1 (sv)
CZ (1) CZ287346B6 (sv)
DE (1) DE69520022T2 (sv)
DK (1) DK0709394T3 (sv)
ES (1) ES2157290T3 (sv)
FI (1) FI113542B (sv)
GR (1) GR3035713T3 (sv)
HU (1) HU221192B1 (sv)
IL (1) IL115659A (sv)
NO (1) NO305252B1 (sv)
NZ (1) NZ280325A (sv)
PL (1) PL187083B1 (sv)
PT (1) PT709394E (sv)
RU (1) RU2168516C2 (sv)
SG (1) SG33569A1 (sv)
TR (1) TR199501327A2 (sv)
TW (1) TW339337B (sv)
ZA (1) ZA958963B (sv)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407082B1 (en) * 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
DE19651000A1 (de) * 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
WO1999061055A1 (en) 1998-05-22 1999-12-02 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and therapies based thereon
US6043235A (en) * 1999-07-21 2000-03-28 Research Triangle Institute 11β-aryl-17, 17-spirothiolane-substituted steroids
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
EP1554572B1 (en) 2001-07-25 2009-10-14 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
CN101287411B (zh) 2005-04-28 2013-03-06 普罗秋斯生物医学公司 药物信息系统及其用途
WO2007035716A2 (en) 2005-09-16 2007-03-29 Raptor Pharmaceutical Inc. Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof
NZ594310A (en) 2009-02-20 2014-02-28 To Bbb Holding B V Glutathione-based drug delivery system
MX2011011833A (es) 2009-05-06 2012-01-27 Lab Skin Care Inc Composiciones de administración dérmica que comprenden complejos de partículas de fosfato de calcio-agente activo y métodos para utilizar las mismas.
US20230202919A1 (en) * 2020-04-03 2023-06-29 Rockwool A/S Method of draining water

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2875199A (en) * 1958-04-22 1959-02-24 Searle & Co Lactones of 17-carboxyalkylated estra-1, 3, 5(10)-triene-3, 17-diols and 3-ethers
US3547912A (en) * 1968-07-29 1970-12-15 American Home Prod Derivatives of 2h-pyran-3(6h)-ones and preparation thereof
US3764596A (en) * 1971-06-22 1973-10-09 Sandoz Ag 17-dihydrofuranyl-substituted steroids
ATE85342T1 (de) * 1987-12-12 1993-02-15 Akzo Nv 11-arylsteroid-derivate.
FR2688004A1 (fr) * 1992-02-27 1993-09-03 Roussel Uclaf Nouveaux sterouides comportant en position 17 un radical methylene lactone, leur procede et des intermediaires de preparation, leur application comme medicaments.

Also Published As

Publication number Publication date
PL187083B1 (pl) 2004-05-31
CN1131158A (zh) 1996-09-18
CA2161490A1 (en) 1996-04-28
EP0709394B1 (en) 2001-01-31
IL115659A0 (en) 1996-01-19
NO305252B1 (no) 1999-04-26
JPH08225590A (ja) 1996-09-03
CZ275595A3 (en) 1996-05-15
FI955108A0 (sv) 1995-10-26
KR100402636B1 (ko) 2004-02-05
DE69520022D1 (de) 2001-03-08
PL311135A1 (en) 1996-04-29
US5741786A (en) 1998-04-21
ZA958963B (en) 1996-05-23
CN1052237C (zh) 2000-05-10
PT709394E (pt) 2001-06-29
ES2157290T3 (es) 2001-08-16
NO954293L (no) 1996-04-29
RU2168516C2 (ru) 2001-06-10
DE69520022T2 (de) 2001-06-13
HU9503068D0 (en) 1995-12-28
CZ287346B6 (en) 2000-10-11
AU3445795A (en) 1996-05-09
FI955108A (sv) 1996-04-28
HUT73482A (en) 1996-08-28
TR199501327A2 (tr) 1996-06-21
ATE199015T1 (de) 2001-02-15
EP0709394A3 (en) 1996-09-18
HU221192B1 (en) 2002-08-28
NZ280325A (en) 1997-03-24
EP0709394A2 (en) 1996-05-01
NO954293D0 (no) 1995-10-26
BR9504576A (pt) 1997-05-20
TW339337B (en) 1998-09-01
SG33569A1 (en) 1996-10-18
AU689642B2 (en) 1998-04-02
GR3035713T3 (en) 2001-07-31
TR199501327A3 (sv) 1996-06-21
KR960014152A (ko) 1996-05-22
DK0709394T3 (da) 2001-06-18
IL115659A (en) 2000-06-01

Similar Documents

Publication Publication Date Title
FI113542B (sv) Steroider som innehåller en 17-spirometylenlaktongrupp
US5292878A (en) 17-spirofuran-3'-ylidene steroids
AU778017B2 (en) 14,15-beta-methylene substituted androgens
KR100341066B1 (ko) 게스타겐활성의19,11-다리결합4-에스트렌
EP1163259B1 (en) 14.beta.,17-alpha-hydroxymethylandrostane derivatives as androgens
KR100400621B1 (ko) 14알파,17알파-c2-브리지된19-노르-프로게스테론유도체
KR100730010B1 (ko) 신규 안드로겐
WO1995011915A1 (de) 10,11β-C2-ÜBERBRÜCKTE STEROIDE

Legal Events

Date Code Title Description
MA Patent expired